GEN Exclusives

More »

GEN Exclusives

More »
Aug 27, 2014

Infographic: Biotherapeutics — Putting Patients First

Learn more about the manufacturing process of biotherapeutics and the current challenges they face in this graphic from the International Federation for Pharmaceutical Manufacturers and Associations (IFPMA).

Infographic: Biotherapeutics — Putting Patients First

  • Undoubtedly, one innovation that has radically transformed medicines is the development of newer, more sophisticated type of drugs produced by living organisms called biotherapeutics. More than 350 biotherapeutic medicines have benefited to date some 400 million patients worldwide. Biotherapeutics lead to more targeted therapies, better diagnostics, and improved outcomes following a patient’s course of treatment for many of the world’s most prevalent diseases, as well as for less common conditions.

    Biotherapeutics include innovative products for the treatment of chronic diseases such as cancer, diabetes, and rheumatoid arthritis, as well as for acute conditions such as myocardial infarction and stroke—and have two common denominators: biological origin and structural complexity. These products bring genuine differences in saving lives, reducing hospitalization, and, ultimately, contributing to healthier societies. 

    The above infographic is brought to you by IFPMA. (If you're having trouble reading the infographic, click here.)


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?